Trial · NCT00824070
Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects
NCT00824070, Phase 1, Completed, Bausch & Lomb Incorporated; results first posted 2010-10-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects. Trials, record NCT00824070. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00824070
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects
- NCT number
- NCT00824070
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 105 participants, actual
- Lead sponsor
- Bausch & Lomb Incorporated
- Conditions
- Cataract Extraction
- Interventions
- Besifloxacin hydrochloride, moxifloxacin hydrochloride, gatifloxacin
- First posted
- 2009-01-16
- Last updated
- 2011-12-13
- Results first posted
- 2010-10-29
- Limitations and caveats
- All drug concentrations were significantly below MIC90 values for relevant staphylococcal species.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Aqueous Humor Drug Concentration. | Visit 2, 1-14 days following screening visit | An aqueous humor specimen was collected from the study eye for determination of drug concentration 60 min after study drug instillation. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Aqueous Humor Drug Concentration. | Visit 2, 1-14 days following screening visit | Statistical Analysis of AH Drug Concentration. Modified intent to treat population (mITT). Subjects with non-missing data. | µg/mL | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Aqueous Humor Drug Concentration. | Besifloxacin | 0.1349 | Standard Deviation 0.5820 | µg/mL | |
| The Aqueous Humor Drug Concentration. | Moxifloxacin | 0.6681 | Standard Deviation 0.4980 | µg/mL | |
| The Aqueous Humor Drug Concentration. | Gatifloxacin | 0.1251 | Standard Deviation 0.07624 | µg/mL |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Besifloxacin | 34 | |
| Overall Study | STARTED | Moxifloxacin | 35 | |
| Overall Study | STARTED | Gatifloxacin | 36 | |
| Overall Study | COMPLETED | Besifloxacin | 34 | |
| Overall Study | COMPLETED | Moxifloxacin | 35 | |
| Overall Study | COMPLETED | Gatifloxacin | 36 | |
| Overall Study | NOT COMPLETED | Besifloxacin | 0 | |
| Overall Study | NOT COMPLETED | Moxifloxacin | 0 | |
| Overall Study | NOT COMPLETED | Gatifloxacin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Besifloxacin | ||
| Total, all-cause mortality | Moxifloxacin | ||
| Total, all-cause mortality | Gatifloxacin | ||
| Total, other adverse events | Besifloxacin | 0 | 34 |
| Total, other adverse events | Moxifloxacin | 0 | 35 |
| Total, other adverse events | Gatifloxacin | 0 | 36 |
| Total, serious adverse events | Besifloxacin | 0 | 34 |
| Total, serious adverse events | Moxifloxacin | 0 | 35 |
| Total, serious adverse events | Gatifloxacin | 0 | 36 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00824070
GET https://conductscience.org/api/trials/v1/NCT00824070/registered